Dave Lahr, PhD, is currently leading the computational biology group at Foghorn Therapeutics, a biotech startup focused on treating diseases by correcting abnormal gene expression. In the early days ...
Skoltech specialists, together with employees of the Kurchatov Institute, discovered the mechanism of action of the ...
NFL Biosciences SA (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing innovative botanical drugs for the treatment of addiction, announces today that it is ...
A new study headed by teams at the Wellcome Sanger Institute, EMBL’s European Bioinformatics Institute (EMBL-EBI), and Open Targets has indicated how mutations that cause cancer drug resistance fall ...
In a study published in the Journal of Extracellular Vesicles, scientists from the UF Health Cancer Institute have found a way to make treatment for a notoriously aggressive breast cancer more ...
Silo Pharma Files Patent Application for Alzheimer's Drug SPC-14 Targeting Novel Mechanism of Action
Silo Pharma, Inc. has announced the filing of a patent application for its neurology drug, SPC-14, which is an intranasal treatment for Alzheimer's disease. This compound, licensed from Columbia ...
Merus N.V., an oncology-focused company, announced the publication of research on petosemtamab, a bispecific antibody targeting EGFR and LGR5, in the journal "Cancers." The study highlights the ...
These sample data illustrate how phenotypic profiles can be used to tease out novel drug mechanisms. A team of Harvard scientists has found a high-throughput way to tie drugs with the cellular ...
HONOLULU — Glovadalen (UCB), an investigational brain-penetrant D1 receptor positive allosteric modulator (D1 PAM), is both safe and effective for patients with advanced Parkinson’s disease (PD), new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results